Pfizer beats out Novo with $10B agreement to buy Metsera

fiercebiotech.com/biotech/pfizer-beats-out-novo-10b-agreement-buy-metsera

After a chaotic and fierce bidding clash that only burst out into public view a little more than a week ago, Pfizer has prevailed in its pursuit of obesity biotech Metsera.
The companies agreed to an acquisition with a value of up to $86.25 per Metsera share, consisting of $65.60 per…

This story appeared on fiercebiotech.com, 2025-11-09 05:45:15.720000.
The Entire Business World on a Single Page. Free to Use →